Previous 10 | Next 10 |
2023-07-06 18:28:00 ET Quanterix ( NASDAQ: QTRX ) said that it has launched a biomarker blood test called LucentAD to help diagnose patients experiencing symptoms consistent with early Alzheimer's disease, or AD. The diagnostics company said the test allows healthcare profession...
2023-07-06 17:10:18 ET The US FDA on Thursday fully approved the Alzheimer's drug Leqembi, developed by Biogen ( NASDAQ: BIIB ) and Eisai ( OTCPK:ESALF ) ( OTCPK:ESAIY ), converting its accelerated approval into a regular approval for patients with mild-to-moderate forms of ...
2023-07-06 09:31:03 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2023-07-04 14:00:00 ET Several drugmakers are eagerly awaiting application decisions from the FDA in July. The most significant decision comes on July 6, when Biogen ( NASDAQ: BIIB ) and Eisai ( OTCPK:ESALF ) will find out if the agency will convert accelerated approval for ...
2023-07-01 16:00:00 ET Buoyed by booming sales of its diabetes drugs, Eli Lilly ( NYSE: LLY ) was the best performing large pharma or biotech in H1 2023, returning an impressive 28% . Coming in second, Vertex Pharmaceuticals ( VRTX ), helped by continued strong revenue f...
Interim results from the RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma ® (onasemnogene abeparvovec) Biogen also reported new real-world evidence and progress on the development of a novel device to enhance the patient treatm...
2023-06-30 15:00:00 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...
2023-06-30 13:15:02 ET Summary Sage Therapeutics, Inc. should find out in August whether its drug targeting major depressive disorder and postpartum depression, zuranolone, will be approved. Zuranolone is being co-developed with Biogen, who made an upfront payment to Sage of $1.5b...
2023-06-30 12:41:16 ET The U.S. government on Friday revised its guidance on the Medicare drug price negotiation program as big pharma fights the newly introduced law in court. The program was introduced late last year under President Biden's Inflation Reduction Act, allowing the Center...
2023-06-27 05:14:31 ET Summary Biogen will find out in July if the FDA has granted its Alzheimer's drug Leqembi full approval. After the Aduhelm fiasco, Biogen has much to prove in the AD space. Partner Eisai has been handling the approval push and launch - more successfully s...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...